Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
28.14
+0.81 (2.96%)
May 13, 2026, 4:00 PM EDT - Market closed
LKFT Revenue
Lakefront Biotherapeutics NV had revenue of 6.48M EUR in the quarter ending March 31, 2026, a decrease of -91.36%. This brings the company's revenue in the last twelve months to 1.04B, up 262.17% year-over-year. In the year 2025, Lakefront Biotherapeutics NV had annual revenue of 1.11B with 303.50% growth.
Revenue (ttm)
1.04B EUR
Revenue Growth
+262.17%
P/S Ratio
1.54
Revenue / Employee
1,870,520 EUR
Employees
558
Market Cap
1.86B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 836.60M | 303.50% |
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 85.33M | 54.73% |
| Dec 31, 2017 | 155.92M | 4.31M | 2.84% |
| Dec 31, 2016 | 151.61M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 899.11M |
| ADMA Biologics | 509.86M |
| Aurinia Pharmaceuticals | 298.30M |
| Syndax Pharmaceuticals | 217.17M |
| Mesoblast | 65.38M |
| Taysha Gene Therapies | 7.47M |
| Oculis Holding AG | 1.51M |
| Inhibrx Biosciences | 1.30M |
LKFT News
- 7 days ago - Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 - GlobeNewsWire
- 6 weeks ago - Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewsWire
- 6 weeks ago - Galapagos Announces Nomination of Gino Santini to its Board of Directors - GlobeNewsWire
- 6 weeks ago - Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings - GlobeNewsWire
- 7 weeks ago - Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewsWire
- 2 months ago - Galapagos Receives Transparency Notification from Bank of America - GlobeNewsWire
- 2 months ago - Galapagos Receives Transparency Notifications from Bank of America - GlobeNewsWire